Amgen Inc. (AMGN) Earnings Call Transcripts
Amgen Inc.'s Latest Earnings Call - Q3 FY2026
In the third quarter of 2026, Amgen Inc. reported total revenues of $10.4 billion, reflecting an 8% year-over-year growth. The company generated $3.7 billion in free cash flow and raised its full-year revenue guidance to a range of $38.9 billion to $39.7 billion, alongside non-GAAP EPS guidance of $22.90 to $23.70. Management highlighted strong performance from its six key growth drivers, which collectively grew 27% year-over-year, indicating robust momentum across its product portfolio and pipeline.
Reported metrics
| Metric | Value |
|---|---|
| Free Cash Flow | $3.7 billion |
| Repatha Sales | $1.1 billion (positive) |
| EVENITY Sales | $751 million (positive) |
| TEZSPIRE Sales | $538 million (positive) |
| UPLIZNA Sales | $451 million (positive) |
| Operating Margin | 47% |
Guidance from management
Amgen raised its 2026 revenue guidance to a range of $38.9 billion to $39.7 billion and non-GAAP EPS guidance to $22.90 to $23.70, reflecting confidence in its ongoing performance and growth potential.
What management said
Thank you Julianne. Good afternoon, everyone, and welcome to our third quarter of 2026 earnings call. Bob Bradway will lead the call today can be followed by a broader review of our performance by Murdo Gordon, Jay Bradner and Thomas Dittrich. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the mater...
I can answer that for you, Terence, it's Bob. Obviously, we consider all options when it comes to managing capacity. But we feel very confident about our ability to continue to be a reliable supplier of high-quality biosimilars. So that's not strain for us and our capacity expansion is really designed for larger quantities of protein than what you're referring to with the biosimilars program. On the other question, J...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for Sjogren's disease treatments and the potential impact of regulatory pathways on new product approvals. There was also discussion around the capacity for biosimilars and how it may affect future growth opportunities.
Main topics on the call
- Revenue Growth Acceleration — Amgen's total revenues reached $10.4 billion in Q3 2026, growing 8% year-over-year. Management noted, "Our 6 key growth drivers grew 27% year-over-year and represented over 70% of our third quarter product sales."
- Strong Performance of Key Products — Repatha and EVENITY showed significant sales growth, with Repatha generating $1.1 billion, up 37% year-over-year, and EVENITY reaching $751 million, a 39% increase. Management stated, "Repatha's momentum continues to acc...
- Pipeline Advancements — Amgen reported positive Phase III results for IMDELLTRA in small cell lung cancer, TEZSPIRE in eosinophilic esophagitis, and dazodalibep in Sjogren's disease. Management emphasized that these results represent "meaningfu...
- Increased R&D Investment — The company increased its R&D spending by 11% year-over-year, reflecting its commitment to innovation. Management noted, "Our strong financial performance gives us the flexibility to invest in innovation and the capabili...
Read the full Amgen Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Amgen Inc.
Amgen Inc. (AMGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 137 calls on record spanning January 9, 2020 to November 3, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 137 Amgen Inc. earnings call transcripts on record, spanning January 9, 2020 to November 3, 2026. Based on this history, Amgen Inc. reports quarterly. The most recent call on file is dated November 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AMGN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 137
- First call
- January 9, 2020
- Most recent
- November 3, 2026
- Reporting cadence
- quarterly